EMA Refused: Masitinib AB Science (Masitinib mesilate) — AB Science

View source ↗

Summary

EMA refused to grant marketing authorization for Masitinib mesilate for amyotrophic lateral sclerosis. The application by AB Science was not approved (decision …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Masitinib mesilate (masitinib)

Snippet

Status: Refused. Therapeutic area: Amyotrophic Lateral Sclerosis. MAH: AB Science. Decision date: 19/12/2024. Orphan medicine